{"id":590727,"date":"2022-03-10T23:30:01","date_gmt":"2022-03-10T23:30:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=590727"},"modified":"2022-03-10T23:30:01","modified_gmt":"2022-03-10T23:30:01","slug":"adalimumab-market-size-share-and-global-market-forecast-to-2029-datamintelligence","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/adalimumab-market-size-share-and-global-market-forecast-to-2029-datamintelligence_590727.html","title":{"rendered":"Adalimumab Market Size, Share and Global Market Forecast to 2029 | DataMIntelligence"},"content":{"rendered":"
\n
\"Adalimumab<\/a><\/div>\n
\n
DataM Intelligence<\/div>\n<\/div>\n<\/div>\n
The Global Adalimumab Market is expected to grow at a high CAGR of 4.8% during the forecasting period (2022-2029).<\/div>\n

Market Overview<\/strong><\/p>\n

Adalimumab is permitted under the emblem called Humira for the treatment of Rheumatoid Arthritis (RA), Juvenile Idiopathic Arthritis (JIA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS), Crohn’s Disease (CD), and Plaque Psoriasis (Ps). Adalimumab is a recombinant human IgG 1 monoclonal antibody that objectives tumour necrosis component (TNF). It acts by using binding to the tumour necrosis factor (TNF) and inhibiting its interaction with the p55 and p75 cellular surface TNF receptors. It lyses floor tumour necrosis thing expressing cells. It is powerful in modulating the organic responses brought about or regulated by using TNF related to the adjustments inside the degrees of adhesion molecules liable for leukocyte migration.<\/p>\n

Adalimumab is evolved by way of using phage display technology resulting in an antibody with human derived heavy and light chain variable areas and human IgG1:k regular regions. It is produced by way of recombinant DNA era in a mammalian cell expression system. It is furnished as both a single-use, prefilled pen or as a single-use, 1 mL stuffed glass syringe.<\/p>\n

 <\/p>\n

Download free sample @ https:\/\/bit.ly\/3sUQS4u<\/a><\/em><\/strong><\/p>\n

 <\/p>\n

Market Dynamics<\/strong><\/p>\n

Rising Prevalence of Autoimmune Disorders is Driving the Growth of the Market<\/em><\/strong><\/p>\n

The marketplace is driven by using the increasing call for adalimumab with the growing occurrence of autoimmune sicknesses. According to the National Stem Cell Foundation (NSCF), approximately 4% of the arena’s population is laid low with one autoimmune disease. Rheumatoid arthritis, ankylosing spondylitis, Crohn’s ailment, psoriatic arthritis, plaque psoriasis, and others are the most not unusual autoimmune illnesses. According to the National Psoriasis Foundation, approximately 2% to 3% of the global populace i.E., 125 million people are tormented by Psoriasis international. Approximately, 30% of sufferers with psoriasis broaden psoriatic arthritis, continual inflammatory arthritis that ends in joint deformations and disability. Ankylosing spondylitis affects around 0.1% and 1.4% of people international. It is most common in men in contrast to ladies. According to the Arthitis Foundation, around eighty% of humans develops the signs of ankylosing spondylitis in the age organization at or earlier than the age of 30 years. Around, five% of patients could increase ankylosing spondylitis within the age institution of 45 or older.<\/p>\n

Favourable Reimbursement Coverage for Adalimumab is Boosting the Market Growth<\/em><\/strong><\/p>\n

The better availability of the compensation insurance for adalimumab shall stimulate market increase. Around, 99% of countrywide commercial, Medicare Part D, and Medicaid sufferers cover the adalimumab. Chinese regulators had also covered adalimumab in the united states of America’s National Reimbursement Drug List (NRDL). Chinese regulators provide e with an average of 61% in price cuts of adalimumab with pharma companies.<\/p>\n

Adverse Effects Associated with the use of Adalimumab is Hampering the Market Growth<\/em><\/strong><\/p>\n

The market is hindered by the adverse effects related to the usage of the adalimumab. Several damaging outcomes together with nausea, abdominal ache, hyperlipidemia, hematuria, hypercholesterolemia, returned pain, rash, headache, high blood pressure, and others are observed among some of the sufferers. Redness, swelling or pain is observed at the site of injection of the adalimumab. It additionally increases the chance of growing fungal, bacterial, and viral contamination which can unfold through the body. Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, parasitic, or other opportunistic pathogens including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis and tuberculosis were determined some of the patients dealt with adalimumab.<\/p>\n

 <\/p>\n

Market Segmentation<\/strong><\/p>\n

By Disease Type<\/p>\n

l Rheumatoid Arthritis (RA)<\/p>\n

l Psoriatic Arthritis (PsA)<\/p>\n

l Crohn’s Disease (CD)<\/p>\n

l Ankylosing Spondylitis (AS)<\/p>\n

l Plaque Psoriasis (Ps)<\/p>\n

l Ulcerative Colitis<\/p>\n

l Others<\/p>\n

 <\/p>\n

By Distribution Channel<\/p>\n

l Hospitals Pharmacies<\/p>\n

l Retail Pharmacies<\/p>\n

l Online Pharmacies<\/p>\n

l Others<\/p>\n

 <\/p>\n

By Region<\/p>\n

l North America<\/p>\n

l Europe<\/p>\n

l South America<\/p>\n

l Asia-Pacific<\/p>\n

l Middle East and Africa<\/p>\n

 <\/p>\n

View full report @ https:\/\/bit.ly\/3tHNhpK<\/a><\/em><\/strong><\/p>\n

 <\/p>\n

Competitive Landscape<\/strong><\/p>\n

The adalimumab market studied is a fragmented market with the presence of a large number of market players. AbbVie Inc, Amgen Inc, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Ltd, F. Hoffmann-La Roche Ltd, Glenmark Pharmaceuticals, Novartis AG, and Pfizer Inc are the major market players with the significant market share. Companies are adopting several growth strategies such as product launches, acquisitions, mergers, collaborations, and licensing for increasing their market presence.<\/p>\n

For instance, In September 2020,  Sensyne Health plc had entered into the collaboration with the University of Oxford for conducting a clinical trial for evaluating the adalimumab for the treatment of COVID-19. Under the terms of the agreement, Sensyne would provide software for remote data collection and analytics for the AVID-CC Phase II clinical trial of the anti-TNF drug adalimumab to prevent respiratory failure due to COVID-19.<\/p>\n

 <\/p>\n

Trending Topic’s<\/em><\/strong><\/p>\n

Anticoagulation Therapy Market<\/em><\/strong><\/a><\/p>\n

Bleeding Disorders Treatment Market<\/em><\/strong><\/a><\/p>\n

Media Contact<\/span>
Company Name:<\/strong> DataM Intelligence<\/a>
Contact Person:<\/strong> Sai
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> +1 877 441 4866
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.datamintelligence.com\/research-report\/adalimumab-market<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

DataM Intelligence The Global Adalimumab Market is expected to grow at a high CAGR of 4.8% during the forecasting period (2022-2029). Market Overview Adalimumab is permitted under the emblem called Humira for the treatment of Rheumatoid Arthritis (RA), Juvenile Idiopathic … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[435,405,406,404,416],"tags":[],"class_list":["post-590727","post","type-post","status-publish","format-standard","hentry","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US","category-World"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/590727","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=590727"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/590727\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=590727"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=590727"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=590727"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}